Neuromuscular Disorders

Bidkar, Prasanna Udupi; Prakash, M.V.S. Satya

doi:10.1016/b978-0-12-805299-0.00045-2

Cited by 3 publications

(2 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuromuscular diseases consist of a diverse group of medical conditions that mainly affect the one or more parts of the neuromuscular unit such as skeletal muscle, motor neurons, peripheral nerves and neuromuscular synapses [ 1 ]. These diseases which can be hereditary or acquired, affect as many as 1 in 3,000 people [ 2 ] and can be attributed to neurodegenerative diseases like Parkinson’s disease (PD) [ 3 ] and Duchenne muscular dystrophies (DMD) [ 4 ]. Most neuromuscular and neurodegenerative disorders tend to impact on locomotion as a result of muscle wasting, weakness and disuse [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Biophysical analysis of drug efficacy on C. elegans models for neurodegenerative and neuromuscular diseases

2021

View full text Add to dashboard Cite

Caenorhabditis elegans has emerged as a powerful model organism for drug screening due to its cellular simplicity, genetic amenability and homology to humans combined with its small size and low cost. Currently, high-throughput drug screening assays are mostly based on image-based phenotyping with the focus on morphological-descriptive traits not exploiting key locomotory parameters of this multicellular model with muscles such as its thrashing force, a critical biophysical parameter when screening drugs for muscle-related diseases. In this study, we demonstrated the use of a micropillar-based force assay chip in combination with a fluorescence assay to evaluate the efficacy of various drugs currently used in treatment of neurodegenerative and neuromuscular diseases. Using this two-dimensional approach, we showed that the force assay was generally more sensitive in measuring efficacy of drug treatment in Duchenne Muscular Dystrophy and Parkinson’s Disease mutant worms as well as partly in Amyotrophic Lateral Sclerosis model. These results underline the potential of our force assay chip in screening of potential drug candidates for the treatment of neurodegenerative and neuromuscular diseases when combined with a fluorescence assay in a two-dimensional analysis approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Biophysical analysis of drug efficacy on C. elegans models for neurodegenerative and neuromuscular diseases

2021

View full text Add to dashboard Cite

show abstract

“…Neuromuscular diseases consist of a diverse group of medical conditions that mainly affect the one or more parts of the neuromuscular unit such as skeletal muscle, motor neurons, peripheral nerves and neuromuscular synapses [1]. These diseases which can be hereditary or acquired, affect as many as 1 in 3,000 people [2] and can be attributed to neurodegenerative diseases like Parkinson's disease (PD) [3] and Duchenne muscular dystrophies (DMD) [4]. A common effect of most neuromuscular disorders is locomotion due to muscle wasting, weakness and disuse [5].…”

Section: Introductionmentioning

confidence: 99%

Quantitative Analysis of Drug Efficacy onC. elegansModels for Neuromuscular Diseases

Sofela

Sahloul

Song

2021

Preprint

View full text Add to dashboard Cite

Caenorhabditis elegans has emerged as a powerful model organism for drug screening due to its cellular simplicity, genetic amenability and homology to humans combined with its small size and low cost. Currently, high-throughput drug screening assays are mostly based on image-based phenotyping not exploiting key locomotory parameters of this multicellular model with muscles such as its thrashing force, a critical parameter when screening drugs for muscle-related diseases. In this study, we demonstrated the use of a micropillar-based force assay chip in combination with an imaging assay to evaluate the efficacy of various drugs currently used in treatment of neuromuscular diseases. Using this two-dimensional approach, we showed that the force assay was generally more sensitive in measuring efficacy of drug treatment in Duchenne Muscular Dystrophy and Parkinson’s Disease mutant worms as well as partly in Amyotrophic Lateral Sclerosis model. These results underline the potential of our force assay chip in screening of potential drug candidates for the treatment of neuromuscular diseases when combined with an imaging assay in a two-dimensional analysis approach.

show abstract

Differential neuropsychological profiles in children and adolescents with motor disability in an inclusive educational setting

García-Castro,

Menor,

Alvarez-Carriles

2024

Child Neuropsychology

View full text Add to dashboard Cite

Neuromuscular Disorders

Cited by 3 publications

References 139 publications

Biophysical analysis of drug efficacy on C. elegans models for neurodegenerative and neuromuscular diseases

Biophysical analysis of drug efficacy on C. elegans models for neurodegenerative and neuromuscular diseases

Quantitative Analysis of Drug Efficacy onC. elegansModels for Neuromuscular Diseases

Differential neuropsychological profiles in children and adolescents with motor disability in an inclusive educational setting

Contact Info

Product

Resources

About